Emergency care for brain AVM bleeding using a hybrid neurosurgical operating room

Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding and Continuous Improvement of Medical Quality Based on Neurosurgery Hybrid Surgery Platform

Observational Beijing Tiantan Hospital · NCT07118631

This study will test whether using a hybrid neurosurgical operating room that combines imaging, endovascular treatment, and microsurgery can provide faster one‑stop emergency care for adults (18–70) with acute brain arteriovenous malformation (AVM) bleeding.

Quick facts

Study typeObservational
Enrollment162 (estimated)
Ages18 Years to 70 Years
SexAll
SponsorBeijing Tiantan Hospital Academic / other
Locations1 site (Beijing)
Trial IDNCT07118631 on ClinicalTrials.gov

What this trial studies

This is a prospective, multicenter registry enrolling adults with acute intracranial hemorrhage thought to be caused by cerebral arteriovenous malformation. Patients treated in the hybrid neurosurgical operating room may receive emergency cerebral angiography, neurointerventional embolization, microsurgical resection of the AVM, and/or minimally invasive hematoma evacuation as clinically indicated. The study will collect clinical and procedural data to characterize indications, workflows, and short‑term functional outcomes. The goal is to develop standardized diagnostic and treatment protocols for emergency AVM hemorrhage management in the hybrid‑OR setting.

Who should consider this trial

Good fit: Adults aged 18–70 with CT‑confirmed intracranial hemorrhage and CTA suggesting AVM, Spetzler‑Martin grade 1–4, who can tolerate surgery and consent to emergency hybrid‑OR treatment are ideal candidates.

Not a fit: Patients who are pregnant or perinatal, have severe underlying disease causing consciousness disorder, or refuse surgery are unlikely to benefit from this hybrid‑OR emergency pathway.

Why it matters

Potential benefit: If successful, this approach could speed coordinated emergency treatment and improve functional outcomes and care consistency for patients with acute AVM bleeding.

How similar studies have performed: Case series and single‑center reports suggest hybrid ORs can speed combined endovascular and surgical care, but high‑quality multicenter registry evidence specifically for acute AVM hemorrhage is limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Head CT confirmed cerebral hemorrhage, with indications for emergency surgery
* Head CTA suggested that the responsible lesion may be cerebral arteriovenous malformation
* Spetzler-Martin classification 1 to 4; Cerebral arteriovenous malformation Spetzler-Martin classification is as follows: ① Nidus size: small (\<3 cm) is scored as 1 point, medium (3 cm\~6 cm) is scored as 2 points, and large (≥6 cm) is scored as 3 points; ② Adjacent brain functional areas: 0 points for non-functional areas, 1 point for functional areas; ③ Drainage veins: 0 points for superficial veins, 1 point for deep veins);
* Aged 18 to 70 years old, with systemic conditions that can tolerate surgery;
* Agree to surgical treatment and sign an informed consent form.

Exclusion Criteria:

* Consciousness disorder due to serious underlying diseases
* Patients or family members who refuse surgery
* Perinatal and pregnancy patients

Where this trial is running

Beijing

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Arteriovenous MalformationBleedingCerebral hemorrhagecerebral arteriovenous malformationhybrid surgeryfunctional prognosisquality improvement system
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.